Monitoring of Irinotecan in Human Plasma: Sensitive Fluorescent Nanogels by Molecular Imprinting

12 June 2019, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A series of fluorescent molecularly imprinted nanogels to detect irinotecan (CPT11) were prepared and characterized. A set of amino acids and napthalimide polymerisable derivatives allowed to obtain polymers as soluble fluorescent nanoparticles by high dilution imprinted synthesis. The direct detection of irinotecan in human plasma was obtained by fluorescence quenching of the naphtalimide-based imprinted materials. The plasma sample treated with acetonitrile allowed the detection of irinotecan in the 10nM – 30μM range. The LOD was 9.4 nM, with within-run variability 10% and day to day variability 13%.

Keywords

irinotecan dosages
Therapeutic Drug Monitoring
Imprinted Polymeric Materials
Biosensor experiments

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.